ORBIS AG

Equities

OBS

DE0005228779

IT Services & Consulting

Market Closed - Xetra 11:36:07 2024-04-26 am EDT 5-day change 1st Jan Change
5.95 EUR 0.00% Intraday chart for ORBIS AG +0.85% +4.39%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ORBIS AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Donald Trump's lawsuit over 'Steele dossier' thrown out by UK court RE
Pola Orbis Plans New Subsidiary in China MT
Trump committed egregious intelligence breach, ex-UK spy tells court RE
Donald Trump's lawsuit over 'Steele dossier' in London court RE
Pola Orbis Holdings' Creates New Subsidiary Pola Medical to Expand its Presence in Aesthetic Medicine Field MT
ORBIS AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Consolidation to boost value of Japan's still fragmented drugstore sector - Orbis RE
Accor sells its stake in Risma in Morocco to Mutris CF
AstraZeneca Says New Drug Application for Breast Cancer Combination Therapy Granted Priority Review by US FDA MT
North American Morning Briefing : Stock Futures Steady Ahead of Inflation Data, Earnings DJ
ORBIS AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Japan Shares Add Profits on Easing South Korea Export Curbs; SoftBank's Arm to Target $8 Billion from US IPO in 2023 MT
Pola Orbis to Wind Up Two Cosmetic Brands MT
Pola Orbis Records 3% Decline in FY22 Attributable Profit MT
ORBIS AG Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Norway's DLTx Sells Stake in Nova Orbis for $1.5 Million MT
Regional REIT Acquires $60 Million Office Properties In UK MT
ORBIS AG Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Bristol-Myers Squibb Says Opdivo-chemotherapy Combination Gets FDA Nod to Treat Non-small Cell Lung Cancer MT
Pola Orbis' FY21 Profit More Than Doubles amid Recovery in Personal Consumption MT
ORBIS AG acquired 60% stake in BLUE STEC GmbH. CI
AstraZeneca's Enhertu Granted Priority Review by US Regulator DJ
AstraZeneca-Daiichi Sankyo's Breast Cancer Drug Accepted For Priority Review in US MT
Cloud Village Raises $400 Million in Sony-Backed Hong Kong IPO Ahead of Dec. 2 Debut MT
Chart ORBIS AG
More charts
ORBIS SE, formerly ORBIS AG, is a Germany-based software and business consultancy company for international corporations and medium-sized enterprises. The Company's service portfolio comprises information technology (IT) strategy consulting services, optimization of business processes and system integration and implementation. It provides IT and software solutions by SAP and Microsoft in the areas of enterprise resource planning (ERP), supply chain management (SCM), logistics, manufacturing execution systems (MES), on site and cloud customer relationship management (CRM), business analytics and product lifecycle management. The Company serves clients from various industries, including automotive, consumer products and retail, pharmaceuticals and machine and plant engineering.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.95 EUR
Average target price
9.1 EUR
Spread / Average Target
+52.94%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. OBS Stock
  4. News ORBIS AG
  5. Pola Orbis Plans New Subsidiary in China